account
Sanofi-Aventis SA will pay $95.5 million to settle allegations that it overcharged state Medicaid programs for anti-inflammatory nasal sprays, the Justice Department announced Thursday.
The settlement resolves charges that between 1995 and 2000 Aventis Pharmaceutical Inc. knowingly misreported its best drug prices to Medicaid programs. Under U.S. law, drug makers are required to report...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
This article has:
- 1 view
Reactions to Sanofi-Aventis Settles Medicaid Price Dispute
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account